TGF-?1 inhibits expression and activity of hENT1 in a nitric oxide-dependent manner in human umbilical vein endothelium

Vega, J. L.; Puebla, C; Vasquez R.; Farias M.; Krause, B; Casanello, P; Sobrevia L.; Alarcon J.; Pastor-Anglada, M

Keywords: reactivity, proteins, growth, endothelium, enzyme, region, complications, expression, transcription, binding, cells, culture, blood, protein, cell, pregnancy, chain, beta, metabolism, humans, factor-beta, human, genetics, receptor, oxide, vasodilation, polymerase, time, methyl, interaction, transporter, female, kinases, rna, vasodilatation, drug, carrier, adenosine, article, kinase, endothelial, factor, promoter, ester, complication, vein, real, activity, genetic, vessel, umbilical, nucleoside, type, controlled, vascular, sp1, study, 4, 1, s, western, tgfb1, amino, priority, Reaction, journal, Receptors,, blotting, Transcription,, 2, (2, nitric, serine, Cells,, Cultured, Messenger, and, beta1, Endothelium,, unclassified, 5, n, 1,2,4, ii, Protein-Serine-Threonine, n(g), nitroarginine, acetyl, Threonine, [2, protein,, transforming, [7, furyl), triazolo[2,3, a][1,3,5]triazin, ylamino]ethyl]phenol, nitrosopenicillamine, Equilibrative, kt, 5823, Regions,, SLC29A1

Abstract

AimsWe studied whether transforming growth factor ?1 (TGF-?1) modulates human equilibrative nucleoside transporters 1 (hENT1) expression and activity in human umbilical vein endothelial cells (HUVECs). hENT1-mediated adenosine transport and expression are reduced in gestational diabetes and hyperglycaemia, conditions associated with increased synthesis and release of nitric oxide (NO) and TGF-?1 in this cell type. TGF-?1 increases NO synthesis via activation of TGF-? receptor type II (T?RII), and NO inhibits hENT1 expression and activity in HUVECs.Methods and resultsHUVECs (passage 2) were used for experiments. Total and hENT1-mediated adenosine transport was measured in the absence or presence of TGF-?1, N G-nitro-l-arginine methyl ester (l-NAME, NO synthase inhibitor), S-nitroso-N-acetyl-l,d-penicillamine (SNAP, NO donor), and/or KT-5823 (protein kinase G inhibitor) in control cells and cells expressing a truncated form of TGF-?1 receptor type II (TT?RII). Western blot and real-time PCR were used to determine hENT1 protein abundance and mRNA expression. SLC29A1 gene promoter and specific protein 1 (Sp1) transcription factor activity was assayed. Vascular reactivity was assayed in endothelium-intact or -denuded umbilical vein rings. TGF-?1 reduced hENT1-mediated adenosine transport, hENT1 protein abundance, hENT1 mRNA expression, and SLC29A1 gene promoter activity, but increased Sp1 binding to DNA. TGF-?1 effect was blocked by l-NAME and KT-5823 and mimicked by SNAP in control cells. However, TGF-?1 was ineffective in cells expressing TT?RII or a mutated Sp1 consensus sequence. Vasodilatation in response to TGF-?1 and S-(4-nitrobenzyl)-6-thio-inosine (an ENT inhibitor) was endothelium-dependent and blocked by KT-5823 and ZM-241385.ConclusionhENT1 is down-regulated by activation of T?RII by TGF-?1 in HUVECs, a phenomenon where NO and Sp1 play key roles. These findings comprise physiological mechanisms that could be important in diseases where TGF-?1 plasma level is increased as in gestational diabetic mothers or patients with diabetes mellitus.

Más información

Título de la Revista: CARDIOVASCULAR RESEARCH
Volumen: 82
Número: 3
Editorial: OXFORD UNIV PRESS
Fecha de publicación: 2009
Página de inicio: 458
Página final: 467
URL: http://www.scopus.com/inward/record.url?eid=2-s2.0-66249130069&partnerID=q2rCbXpz